Fatty liver drug showdown: ornithine aspartate vs silymarin

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Consistent with NAFLD diagnosis criteria, and during previous one month, the B-mode ultrasonography showed diffuse fatty liver and Fibroscan test showed that CAP value \> 248 db/m; * 2\. During previous one month, serum ALT level was higher than 1.5 times the upper limit of normal. * 3\. BMI is not more than 30 kg/m2. * 4\. Voluntary to participate in the research and signed a written informed consent to comply with the trial protocol. Exclusion Criteria: * 1\. Hereditary metabolic or autoimmune liver disease, hepatotropic and non-hepatotropic virus infection, drug/toxic/alcoholic/biliary liver injury, or any end-stage liver disease; fatty liver disease caused by one of the following reasons: total parenteral nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome, beta-lipoprotein deficiency and some insulin resistance (IR) related syndromes (lipid atrophic diabetes, Mauriac syndrome); * 2\. Hepatic or extrahepatic malignant tumors; * 3\. Severe heart failure or renal failure (serum creatinine \> 3mg/100mL); * 4\. Allergic constitution, or allergic to amino acid drugs or to ornithine aspartate and its constituents or to silymarin; * 5\. ALT or γ-glutamyl transpeptidase (γ-GT) are greater than 5 times the upper limit of normal, or total bilirubin (TBIL) \> 51 umol/L.; * 6\. Confirmed liver cirrhosis or Fibroscan test showed E value \> 12.5 kilopascal (KPa); * 7\. Triglyceride \> 5.6mmol/L; * 8\. Diabetes diagnosed for more than 5 years, combined with current insulin therapy or taking hypoglycemic drugs with poorly controlled condition (HbA1c \> 9%). * 9\. Women who are pregnant, nursing or preparing for pregnancy; * 10\. Suspected or confirmed excessive drinking (equivalent alcohol amount: male, \> 40g/d; female, \> 20g/d), or history of drug abuse; * 11\. Combined use of drugs with liver protection and anti-inflammatory effects, as well as any Chinese patent medicine, Chinese herbal medicine, or health products that may have liver protection or liver damage effects; * 12\. Taking weight-loss drugs or receiving weight-loss treatment; * 13\. Situations of inappropriate participation judged by researchers.